D. Western Therapeutics Institute, Inc. (TYO:4576)
98.00
-2.00 (-2.00%)
At close: Feb 6, 2026
TYO:4576 Revenue
D. Western Therapeutics Institute had revenue of 123.86M JPY in the quarter ending September 30, 2025, a decrease of -1.22%. This brings the company's revenue in the last twelve months to 419.76M, down -9.39% year-over-year. In the year 2024, D. Western Therapeutics Institute had annual revenue of 471.00M with 10.05% growth.
Revenue (ttm)
419.76M
Revenue Growth
-9.39%
P/S Ratio
12.67
Revenue / Employee
19.99M
Employees
21
Market Cap
5.32B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 471.00M | 43.00M | 10.05% |
| Dec 31, 2023 | 428.00M | -20.00M | -4.46% |
| Dec 31, 2022 | 448.00M | 34.00M | 8.21% |
| Dec 31, 2021 | 414.00M | 59.00M | 16.62% |
| Dec 31, 2020 | 355.00M | -225.00M | -38.79% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Transgenic Group | 12.92B |
| Linical | 9.87B |
| Kohjin Bio | 5.20B |
| Soiken Holdings | 4.87B |
| OncoTherapy Science | 956.00M |
| PRISM BioLab Co.,LTD | 677.33M |
| Carna Biosciences | 544.45M |
| Noile-Immune Biotech | 7.00M |